Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRB | P28702 | 3/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GCK | P35557 | 1/20 | 0.37 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21906327 | 0.88 | HSPB1 (0.51) | RXRBMETMAPK1HSPB1KDM4E | |
| SCHEMBL21906677 | 0.87 | RXRB (0.45) | RXRBMAPK1MRGPRX4KDM4EGCK | |
| SCHEMBL21906688 | 0.86 | RXRB (0.47) | RXRBMETMAPK1HSPB1MRGPRX4 | |
| SCHEMBL14659263 | 0.83 | MEN1 (0.48) | RXRBMAPK1KDM4EGCK | |
| SCHEMBL21906516 | 0.82 | OXTR (0.47) | RXRBMAPK1HSPB1 | |
| SCHEMBL23437456 | 0.80 | MET (0.41) | METMAPK1MRGPRX4GRIN2BGRIN1 | |
| SCHEMBL16762015 | 0.78 | CHRNA7 (0.50) | RXRBMAPK1KDM4E | |
| SCHEMBL30879524 | 0.78 | CHRNA7 (0.50) | RXRBMAPK1KDM4E | |
| SCHEMBL21906524 | 0.76 | RXRB (0.43) | RXRBMAPK1KDM4EGCK | |
| SCHEMBL21906512 | 0.75 | RXRB (0.51) | RXRBRAF1METHSPB1MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3867244-B1 | 4-PYRAZIN-2-YLMETHYL-MORPHOLINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INT (DE) | 2023-01-18 | — | — | EP | disclosed |
| US-20210393644-A1 | 4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM INT (DE) | 2021-12-23 | — | — | US | disclosed |
| US-11166958-B2 | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-11-09 | — | — | US | disclosed |
| US-20200121691-A1 | 4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-04-23 | — | — | US | disclosed |
| WO-2020079039-A1 | 4-PYRAZIN-2-YLMETHYL-MORPHOLINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200121691-A1 | 4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | GRIN2A, GRIN2C, GRIN3A | RXRB 595/4885RAF1 2967/4885MET 1137/4885 |
| US-20210393644-A1 | 4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | GRIN2A, GRIN2C, GRIN3A | RXRB 595/4885RAF1 2967/4885MET 1137/4885 |
| US-11166958-B2 | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | GRIN2A, GRIN2C, GRIN3A | RXRB 595/4885RAF1 2967/4885MET 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.